Distribution and antifungal resistance rate of yeast isolated from various samples
Article Sidebar
Main Article Content
Abstract
Objective: Yeast causes hospital-acquired infections at increasing rates, which can cause serious mortality, especially in patients with a suppressed immune system. This study aimed to determine the species distribution and antifungal resistance rates of yeast isolated in a hospital.
Material and Methods: Isolated yeasts from clinical specimens of patients who received inpatient treatment in different clinics in our hospital between 1 December 2019 and 30 September 2020 were examined. In all of these isolates, species identification was made with an automated system in addition to classical methods. Additionally, the antifungal susceptibility of yeast against amphotericin B, flucytosine, Fluconazole, micafungin, caspofungin, and Voriconazole was investigated using an automated system.
Results: In the study, yeasts isolated from 183 clinical samples, including 64 vagen, 62 blood, 28 urine, 12 wounds, eight tracheal aspirates, five peritoneal fluids, three catheters and one cerebrospinal fluid (CSF) samples were included. Of these isolates, 93 were Candida albicans (50,82%), 40 were Candida parapsilosis (21,86%), 17 were Candida tropicalis (9,29%), eight were Candida glabrata (4,37%), eight were Stephanoascus ciferrii (4,37%), five were Candida lusitaniae (2,19%), four were Candida famata (2,19%), four were Cryptococcus laurentii (2,19%) and four were Candida krusei ( 2,19%). Antifungal susceptibility testing was performed in 103 of the isolates. The highest resistance was found against Fluconazole, with 16.8%, and the lowest resistance was against flucytosine, with 2.2%. Antifungal resistance rates of Fluconazole, Voriconazole, amphotericin B, flucytosine, caspofungin and micafungin were found as 16.8%, 8.2%, 6.1%, 2.2%, 2.9% and 6.8% respectively.
Conclusion: Due to the increasing frequency of fungal infections due to long-term hospitalization, it has been concluded that identifying the causative species and reporting the antifungal susceptibility status is important in monitoring the change in resistance rates and guiding the treatment.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2023-04-08
Published 2023-04-11
References
Çiçek B, Yılmaz H, Mutlu Yılmaz E, Esen Ş, Birinci A. Investigation of changes in the epidemiology of candida. Microbiol Bul. 2015;49(3):423-31.
Fungiscope. Global Emerging Fungal Infection Registry. Available online: http://www.fungiscope.net/ (accessed on 11 December 2021).
Young GE, Özel S, Erturan Z. Investigation of the Frequency of Oral Candida Colonization in Healthy Individuals. ANKEM Derg. 2014;28(1):26-31.
Gültekin B, Eyigör M, Telli M, Aksoy M, Aydın N. Retrospective Investigation of Candida Species Isolated from Blood Cultures in the Seven-Year Period. ANKEM Derg. 2010;24(4):202-8.
Seyedmousavi S, İlkit M, Durd M, Ergin Ç, Hilmioğlu-Polat S, Melchers W, Verweİj P. Candida and Candidosis: Epidemiology, Diagnosis, Treatment, Current Status in Antifungal Drug Resistance and Genetic Predisposition of the Host: Türk Mikrobiyol Cem Derg. 2015;45(1):1-11.
Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134-40.
Rather N, Elgören N, Arslan MN. Distribution and antifungal susceptibility of yeast species isolated from various Postmortem samples. Turkish Microbiology Cem Derg. 2019;49(3):147-53.
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED) Antifungal Resistance in Candida. https://www.cdc.gov/ncezid/may 18;2020 (Date of access 05.08.2022)
Toda M, Williams SR, Berkow EL, Farley MM, Harrison LH, Bonner L, et al. Population-based active surveillance for culture-confirmed candidemia — four sites, United States, 2012–2016. MMWR Surveill Summ. 2019;68(8):1-15.
Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(Jun 15):1724-32.
Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother. 2008;52(9):3022-8.
Ayhancı T, Altındiş M. Rapidly spreading multidrug-resistant yeast fungus: Candida auris: Turkish Journal of Hygiene and Experimental Biology Turkish Hij. Den Biyol Derg, 2020;77(1): 123-36.
Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2018;31(1): e00029-17.
Koehler P, Arendrup MC, Arikan-Akdagli S, et al. ECMM Candi Reg-A ready to use platform for outbreaks and epidemiological studies. Mycoses. 2019; 62:920-7.
Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-4
Prosecutor Ü, Yılmaz N. Species distribution and antifungal resistance rates of Candidas isolated from various samples. Turk J Clin Lab. 2017;8( 3):85-90.
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Antifungal Agent breakpointtales for interpretation of MICs Version 9 valid from 2018-02-08. https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals
Özbek E, Tekay F, Çolak Pirinççioğlu H. Antifungal resistance in Candida isolates isolated from various samples of intensive care patients. Dicle Medical Derg. 2012;39(2)212-17.
Galia L, Pezzani MD, Compri M, Callegari A, Babu Rajendran N, Carrara E, Tacconelli E and the COMBACTE MAGNET EPI-Net Network. Surveillance of Antifungal Resistance in Candidemia Fails to Inform Antifungal Stewardship in European Countries. J Fungi. 2022; 8:249. J. Fungi 2022, 8(3), 249; https://doi.org/10.3390/jof8030249
Erdem I, Oguzoglu N, Ozturk Engin D, et al. Incidence, Etiology and Risk Factors Associated with Mortality of Nosocomial Candidemia in a Tertiary Care Hospital in Istanbul, Turkey. Medical Principles and Practice. 2010;19(6):463-7.
Yapar N Uysal Ü, Yücesoy M, Çakır N., Yüce A. Nosocomial bloodstream infections associated with Candida species in a Turkish University Hospital. Mycoses. 2006;49(2):134-8.
Yenigün Koçak B, Kuloğlu F, Doğan Çelik A, Akata F. Evaluation of Epidemiological Features and Risk Factors of Adult Candidemia Cases in a Tertiary Care Hospital. Microbiol Bul. 2011;45(3):489-503.
Berkow EL, Lockhart SR, Ostrosky-Zeichner L: Antifungal Susceptibility Testing: Current Approaches. Clin. Microbiol Rev. 2020;33: e00069-19.
Çalışkan E, Dede A, Biten Güven G. Distribution and Antifungal Sensitivities of Candida Species Detected in Blood Cultures. ANKEM Derg. 2013;27(1):25-30.
Etiz P, Kibar F, Ekenoğlu Y, Yaman A. Retrospective Evaluation of the Distribution and Antifungal Sensitivity of Candida Species Isolated from Blood Cultures. ANKEM Derg. 2015;29(3):105-13.
Beder D, EsenkayaTaşbent F, Doğan M. Distribution and antifungal sensitivities of Candida isolates detected in blood cultures: ANKEM Derg. 2020;34(3):77-85.
Er H, Özkalay Yılmaz N, Karaca Derici Y, Hancı S, Saba Çopur Ş. Species Distribution and Sensitivities of Candidemia Agents: Should Empirical Antifungal Treatment Policy Be Changed in Our Hospital. Turk Mikrobiyol Cemiy Derg. 2021;51(2):150-5